Lunasin abrogates the expression of matrix metalloproteinases and reduction of type II collagen

Abstract

Impairment of type II collagen caused by MMPs in response to overproduction of IL-1β is an important step in the pathological progression of osteoarthritis (OA). Lunasin, a well-known peptide present in the soybean, has displayed a positive impact on numerous physiological functions. Little information in the effects of lunasin on cartilage degradation has been sought in clinical research before. Here, we report that lunasin suppressed the increase in MMP-3 and MMP-13 caused by IL-1β. In addition, we found that lunasin could prevent the decrease in TIMP-1 and TIMP-2 expressions caused by IL-1β. Notably, lunasin suppressed reduction of type II collagen, the basis for articular cartilage. Lunasin also attenuated activation of the JAK2/STAT1/IRF-1 pathway. These effects of lunasin suggest that it might become a promising therapeutic agent for chondro-protective therapy.

Keywords:

• Osteoarthritis
• lunasin
• matrix metalloproteinases
• type II collagen

Introduction

Osteoarthritis (OA) is commonly seen in the elderly, and it affects millions of the population worldwide. Multiple biochemical and mechanical factors contribute to the initiation of OA [1]. Mild inflammation associated with overproduction of IL-1β plays a critical role in the pathological progression of OA. IL-1β results in the induction of matrix metalloproteinases (MMPs) and nitric oxide (NO) in chondrocytes. MMPs have been recognized as crucial factors in OA [2]. Among them, MMP-3 and MMP-13 act as the two most important collagenases involved in the degradation of the cartilage matrix in OA [3]. MMP-3 can cleave multiple extracellular matrices including proteoglycans [4]. MMP-13 is responsible for the digestion of type II collagen [5,6]. The physiological activities of MMPs are antagonized by tissue inhibitors of metalloproteinases (TIMPs), such as TIMP-1 and TIMP-2 [7]. Inhibiting the activity of MMPs and degradation of ECM has become a promising strategy to blunt OA progression.

Lunasin, a well-known natural peptide, was found in the soybean [7]. It has displayed positive impacts on numerous physiological functions in living beings. Increasing evidence shows that lunasin has protective properties that are effective in the treatment of various diseases, including neurodegenerative diseases, heart disease and bone disorders [8]. Patents taking lunasin have demonstrated that this peptide exhibits a diverse range of biological activities, which include anti-inflammatory, anti-diabetes and anti-cancer properties [9]. Due to these beneficial roles, numerous nutritional supplements containing lunasin are offered. It has been identified that daily dietary supplementation with 125 mg lunasin exerts protective effects in terms of heart health and cholesterol management. Additionally, a kind of lunasin extract from Mexico has been successfully applied for developing soy beverages and functional foods [10]. The anti-inflammatory function of lunasin has been studied in recent investigations. Significantly, lunasin could inhibit the secretion of IL-1β [11]. However, the pharmacological role of lunasin in OA has not been known. Here, we report that lunasin treatment prevented IL-1β-mediated loss of type II collagen by inhibiting MMP-3 and MMP-13.

Materials and methods

Cell isolation and treatment

Normal knee joint cartilage was obtained from transplant donors (n = 21) who were undergoing joint cartilage head replacement surgeries. The cartilage was cut and the samples were digested with 0.2% collagenase at 37 °C for 4 h. Isolated chondrocytes were grown in DMEM with 10% FBS and 0.1% antibiotics. Lunasin was provided by KaiJie Bio (Chengdu, China). Analytical HPLC and ESI-MS was used for quality control of the synthesized lunasin by the manufacturer. The purity of lunasin was higher than 95% (Impurities: undesired fragments of peptides generated in the process of chemical synthesis with different molecular weights). Cells were cultured with IL-1β (10 ng/ml) with or without lunasin (50, 100 μM).

Cell proliferation measurement

After the indicated treatments, MTT reduction assay was performed to examine cell proliferation [12]. Briefly, cells were grown in 96-well culture plates. After stimulation, we put 1 mg/mL MTT to the culture medium for 3 h in darkness. One-hundred microlitre of dimethyl sulphoxide was used to dissolve the resultant insoluble products. OD at 490 nm was detected using a microtitre plate reader (model 680, Bio-Rad, UK).

Real-time PCR

Real-time PCR was performed as previously reported in other studies [13]. Qiazol was used to isolate total RNA from chondrocytes. RNA concentration was assessed by measuring the A260/A280 ratio. Reverse transcription PCR was performed to synthesize cDNA with 1 μg total RNA. Experiment was carried out using cDNA template, primers and the SYBR green master mix system (12.5 µl). Assay precision has been verified at the dynamic range over which a reaction is linear [14]. Quantification was achieved by normalizing the target gene to GAPDH using the 2^–ΔΔCT method and compared with the control.

Western blot analysis

Chondrocytes were lysed. Protein concentration was assessed using a BCA assay. 20 μg samples were subjected to 8% SDS-PAGE and transferred to PVDF membranes. After blocking, blots were incubated with antibodies against IRF-1, p-JAK2, type II collagen, JAK2, MMP-3, p-STAT1, MMP-13, STAT1 and β-actin overnight in a cold room. Membranes were then probed with the secondary HRP-conjugated antibodies. The blots were developed using ECL [15].

Determination of MMP concentrations

The secretion of active MMP-3 and MMP-13 was assessed using a commercially available ELISA kit (AnaSpec, USA). The fluorescence of 5-FAM was read and monitored (excitation: 490 nm; emission: 520 nm).

Statistical analysis

Experimental data are presented as means ± SD. Data were assessed by ANOVA. Differences were thought as significant when p was <.05.

Results

To evaluate the effects of lunasin on proliferation of chondrocytes, a MTT assay was performed. Our results indicate that the administration of lunasin at final concentrations of 50 and 100 μM did not affect cell proliferation of chondrocytes. However, mean cell proliferation was reduced by 18% (p < .01) after treatment with lunasin using the final concentration of 500 μM (Figure 1(A)). Notably, administration of lunasin at final concentrations of 50 and 100 μM did not have any impact on basal levels of MMP-3 and MMP-13 (Figure S1). Therefore, we administered lunasin at concentrations of 50 and 100 μM. First, we examined whether lunasin affects the inhibitory role of IL-1β on chondrocytes proliferation. We demonstrate that IL-1β treatment (48 h) remarkably reduced cell proliferation by 45% (p < .01), which was prevented by lunasin (Figure 1(B)). We then profiled the levels of MMP-3 and MMP-13 after IL-1β stimulation in the absence or presence of lunasin. Results shown in Figure 2(A) indicate that following treatment with IL-1β, mRNA levels of MMP-3 and MMP-13 had increased 4.5 and 5.1 times, respectively. This was prevented by lunasin. Consistently, ELISA assay revealed that the secretion of these enzymes was elevated after IL-1β treatment, which was suppressed by lunasin (Figure 2(B)). The biological activities of MMPs are mainly inhibited by TIMP-1 and TIMP-2. Therefore, we determined the roles of lunasin on TIMP-1 and TIMP-2. Results in Figure 3(A) show that IL-1β remarkably decreased TIMP-1 and TIMP-2 at the mRNA level by 69% and 65%, respectively, which was obviously prevented by lunasin. Consistently, the presence of lunasin restored the protein expression of these two TIMPs (Figure 3(B)).

Figure 1. Lunasin ameliorated IL-1β-mediated reduction of cell proliferation. (A) Chondrocytes were incubated with lunasin (50, 100 and 500 μM) for 48 h. Cell proliferation was assessed by MTT. (B) Chondrocytes were cultured with IL-1β with or without lunasin (50, 100 μM). Chondrocytes proliferation was examined with MTT (*, #, p < .01).

Figure 2. Lunasin ameliorated IL-1β-mediated induction of MMPs. Chondrocytes were stimulated with IL-1β or lunasin (50, 100 μM). (A) mRNA level of MMP-3, MMP-13. (B) Protein level of MMP-3, MMP-13 (*, #, p < .01).

Figure 3. Lunasin ameliorated IL-1β-mediated decrease in TIMP-1 and TIMP-2. Chondrocytes were stimulated with IL-1β or lunasin (50, 100 μM). (A) mRNA level of TIMP-1, TIMP-2. (B) Protein level of TIMP-1, TIMP-2 (*, #, p < .01).

The level of type II collagen was reduced by 59% (p < .01) after IL-1β treatment. As expected, lunasin suppressed IL-1β-mediated loss of type II collagen (Figure 4). MMP-3 and MMP-13 are transcriptionally governed by IRF-1. Hence, we investigated whether lunasin affects the levels of IRF-1. Notably, we found that treatment with lunasin abolished the upregulation of IRF-1 (Figure 5). The JAK2/STAT1 pathway is important for the activation of IRF-1. Significantly, it was shown that IL-1β treatment markedly elevated the phosphorylation of JAK2 by 2.5 times (p < .05) as well as STAT1 at Ser727 by 2.1 times (p < .05), which was reduced by lunasin (Figure 6(A,B)). These results imply that lunasin might suppress the expression of MMPs by inhibiting activation of the JAK2/STAT1/IRF-1 pathway. To further confirm the participation of this pathway, cells were incubated with IL-1β and lunasin (100 μM) with or without the specific JAK2 activator coumermycin A1 (50 nM) or the specific JAK2 inhibitor AG490 (10 nM). Results display that the presence of coumermycin A1 negated the effects of lunasin on MMPs expression (Figure 7). In contrast, AG490 enhanced the inhibitory effects of lunasin on MMPs expression. This suggests the participation of the JAK2/STAT1/IRF-1 pathway in these processes.

Figure 4. Lunasin mitigated IL-1β caused reduction of type II collagen. Chondrocytes were stimulated with IL-1β or lunasin (50, 100 μM). Col II, type II collagen. (A) Representative bands of type II collagen. (B) Quantitative analysis (*, #, p < .01).

Figure 5. Lunasin abolished IL-1β-induced upregulation of IRF-1. Chondrocytes were stimulated with IL-1β or lunasin (50, 100 μM). (A) mRNA level of IRF-1. (B) Protein level of IRF-1 (*, #, p < .01).

Figure 6. Lunasin suppressed IL-1β- induced activation of JAK2 and STAT1. Chondrocytes were stimulated with IL-1β or lunasin (50, 100 μM). (A) Representative bands of phosphorylated JAK2 and STAT1 at Ser 727, (B) Quantitative analysis (*, #, p < .01).

Figure 7. The JAK2/STAT1/IRF-1 pathway participates in the inhibitory effects of lunasin on MMPs. Chondrocytes were cultured with IL-1β and lunasin (100 μM) with or without the specific JAK2 activator coumermycin A1 (50 nM) or the specific JAK2 inhibitor AG490 (10 nM) for 24 h. (A) mRNA levels of MMPs. (B) Protein levels of MMPs (*, #, $, p < .01).

Discussion

Here, we provide evidence to identify a new pharmacological function of lunasin in abrogating ECM degradation in chondrocytes. First, we found that lunasin inhibited MMP-3 and MMP-13. Second, it was shown that lunasin reversed the decrease in TIMP-1 and TIMP-2. Third, lunasin abrogated IL-1β-induced activation of IRF-1 by regulating the JAK2/STAT1 pathway. A graphical explanation of the molecular mechanism is presented in Figure 8.

Figure 8. A graphical representation of the underlying mechanism.

MMPs are essential enzymes that play key roles in regulating the balance of the extracellular matrix metabolism. Under normal physiological conditions, they assist in the creation and maintenance of interstitial spaces. Under pathological conditions, they cause excessive degradation of extracellular matrix proteins by facilitating multiple inflammatory processes [16]. Among them, MMP-3 is capable of cleaving proteoglycans, collagens, gelatins and aggrecan link proteins. MMP-13 is another important enzyme capable of efficiently degrading type II collagen and aggrecans in cartilage. Selective MMP-13 inhibitors have been reported to block degradation of type II collagen [17,18]. An equilibrium of MMPs and TIMPs is necessary for maintaining the integrity of articular cartilage [19–22]. It should be noted that treatment with lunasin alone at the concentrations of 50 and 100 μM did not affect the basal levels of MMPs under normal conditions (Figure S1). However, when cells were exposed to IL-1β, lunasin significantly prevented the induction of MMP-3 and MMP-13 (Figure 2). These results suggest that lunasin displays a strong protective effect against inflammatory stimuli by activating anti-inflammatory signalling in cells. In the current study, we report that lunasin treatment increased expression of TIMP-1 and TIMP-2, while decreasing expression levels of MMP-3 and MMP-13. Indeed, our subsequent study demonstrates that lunasin abrogated degradation of its substrate type II collagen. Lunasin could suppress the generation of lipopolysaccharide (LPS)-induced inflammation markers by suppressing the central inflammation regulator NF-κB [23]. Furthermore, lunasin reduces the secretion of TNF-α and IL-6 and the generation of ROS [11]. Interestingly, lunasin displays its anti-inflammatory property by suppressing IL-6, TNF-α and MCP-1 not only in RAW264.7 macrophages but also in 3T3-L1 adipocytes [24]. Lunasin was shown to suppress cell proliferation and induce apoptosis of rheumatoid arthritis (RA) synovial fibroblasts [25]. Lunasin-enriched preparation prevented inflammasomes activation by decreasing IL-1β, IL-18 and ROS in macrophages [26]. Notably, lunasin could inhibit the migration of human MCF-7 cells [27]. RGD-peptide lunasin reduced pro-inflammatory factors through regulating αVβ3 integrin in human and murine macrophages [28–32]. Integrins such as β1 and αvβ3 subunits play a role in mechanotransduction and in the ability of chondrocytes to sense the local microenvironment [33]. These results suggest that suppression of integrin signalling by lunasin might be involved in the effects of lunasin against IL-1β-caused reduction of type II collagen.

Although a number of novel bioactivities of lunasin have been reported over the past decade, there are still certain limitations and challenges. Firstly, existing findings including our results regarding the pharmacological capacities of lunasin are still not mature. A number of these findings have only been reported by individual scientists. Secondly, most of the current findings on the protective effects of lunasin are based on in vitro and animal models. Evidence from human experiments is limited. Thus, future clinical trials are necessary to study the benefits and side effects of this peptide.

In conclusion, our results provide evidence of the chondroprotective effects and abilities of lunasin. These results suggest that lunasin might become a novel pharmacological agent for chondroprotective therapy.

Disclosure statement

No potential conflict of interest was reported by the authors.